Apr 6, 2020 7:00 am EDT Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference
Apr 1, 2020 7:00 am EDT Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk
Mar 27, 2020 3:07 pm EDT Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic
Mar 26, 2020 7:00 am EDT Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma
Mar 5, 2020 7:00 am EST Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma
Feb 25, 2020 7:00 am EST Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020
Feb 12, 2020 7:00 am EST Castle Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Jan 20, 2020 7:00 am EST Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma
